TY - JOUR
T1 - Effect of adaptive servoventilation on muscle sympathetic nerve activity in patients with chronic heart failure and central sleep apnea
AU - Joho, Shuji
AU - Oda, Yoshitaka
AU - Ushijima, Ryuichi
AU - Hirai, Tadakazu
AU - Inoue, Hiroshi
PY - 2012/10
Y1 - 2012/10
N2 - Background: Adaptive servoventilation (ASV) improves cardiac function and sympathetic nerve activity in patients with heart failure (HF). However, the mechanisms underlying these improvements remain obscure. Methods and Results: We compared muscle sympathetic nerve activity (MSNA) and cardiorespiratory polygraphy and echocardiography findings at baseline and at 3.5 ± 0.8 months' follow-up in 32 patients with HF (New York Heart Association functional class II or III; ejection fraction <45%) and central sleep apnea (CSA; apnea-hypopnea index [AHI] ≥15/h) who consented (n = 20; ASV group) or declined (n = 12; non-ASV group) to undergo ASV treatment. Compliance with ASV and changes in AHI were determined from data collected by integral counters in devices and from cardiorespiratory polygraphic findings, respectively. Ejection fraction and MSNA significantly changed in the ASV (both P <.001) but not the non-ASV group. Although changes in AHI and MSNA correlated, the average use of ASV did not. In contrast, changes in AHI and the average use of ASV were independent predictors of changes in ejection fraction (both P <.01). Conclusions: ASV decreases MSNA and improves cardiac function in association with suppression of CSA in patients with HF.
AB - Background: Adaptive servoventilation (ASV) improves cardiac function and sympathetic nerve activity in patients with heart failure (HF). However, the mechanisms underlying these improvements remain obscure. Methods and Results: We compared muscle sympathetic nerve activity (MSNA) and cardiorespiratory polygraphy and echocardiography findings at baseline and at 3.5 ± 0.8 months' follow-up in 32 patients with HF (New York Heart Association functional class II or III; ejection fraction <45%) and central sleep apnea (CSA; apnea-hypopnea index [AHI] ≥15/h) who consented (n = 20; ASV group) or declined (n = 12; non-ASV group) to undergo ASV treatment. Compliance with ASV and changes in AHI were determined from data collected by integral counters in devices and from cardiorespiratory polygraphic findings, respectively. Ejection fraction and MSNA significantly changed in the ASV (both P <.001) but not the non-ASV group. Although changes in AHI and MSNA correlated, the average use of ASV did not. In contrast, changes in AHI and the average use of ASV were independent predictors of changes in ejection fraction (both P <.01). Conclusions: ASV decreases MSNA and improves cardiac function in association with suppression of CSA in patients with HF.
KW - Sleep-disordered breathing
KW - cardiovascular diseases
UR - http://www.scopus.com/inward/record.url?scp=84867148223&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2012.08.360
DO - 10.1016/j.cardfail.2012.08.360
M3 - 学術論文
C2 - 23040112
AN - SCOPUS:84867148223
SN - 1071-9164
VL - 18
SP - 769
EP - 775
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 10
ER -